What changed
The classification became applicable on November 8, 2023, after FDA reviewed Owlet Baby Care's De Novo request for the Dream Sock. The new order codifies requirements for the generic device type rather than making a fresh product-level judgment.
This device type uses light-based sensing, known as photoplethysmography, to measure an infant's pulse rate and oxygen saturation. Some monitors may sound an alarm when a reading crosses a preset threshold. FDA placed the category in class II because general controls alone were insufficient, while specific added controls could provide reasonable assurance of safety and effectiveness. The category remains subject to 510(k) premarket notification. A future manufacturer may use the classified device as a predicate if it can establish substantial equivalence.
Why it matters
FDA's controls follow the whole chain from skin contact to human action. Manufacturers must provide clinical performance data under anticipated conditions of use and examine confounders such as skin pigmentation. They must explain whether data sources are representative and how data quality was judged.
The software requirements reach into algorithm inputs and outputs, acceptable incoming sensor data, verification, validation, and hazard analysis. Separate testing must address signal quality and alarm performance. The order also calls for caregiver human-factors testing and labeling that explains limitations, interpretation, appropriate next steps, and cleaning.
That combination matters because a technically plausible reading can still produce a bad outcome if the signal is weak, the alert is misunderstood, or a caregiver places too much confidence in the device. FDA lists false positives, false negatives, poor signal quality, misinterpretation, overreliance, and use error among the risks it expects the controls to address.
Verification bottleneck
The public order defines the evidence a manufacturer must produce. It does not establish the performance of every monitor on the market or endorse a specific product. Product-level evidence belongs in the relevant clearance record, labeling, and postmarket history.
This leaves an important gap for parents and other caregivers. A device may reduce a stream of sensor data to a simple alert, but the user still needs to know whether the signal is trustworthy, what the alert means, and when the device has reached the edge of what it can tell them. The regulation recognizes that handoff as part of device safety.
Watch next
Future 510(k) summaries and product labels should show how manufacturers respond to these controls. Useful details will include the conditions used in clinical testing, representation across skin pigmentation, treatment of weak or missing signals, alarm thresholds, and the results of caregiver usability studies. Postmarket reports can then show whether false alerts, missed alerts, and interpretation problems appear in ordinary use.
This card covers a final order for a generic device type. It does not assess any specific product and is not medical advice.
Source
U.S. Food and Drug Administration, "Medical Devices; Cardiovascular Devices; Classification of the Infant Pulse Rate and Oxygen Saturation Monitor for Over-the-Counter Use," Federal Register, October 9, 2026. https://www.federalregister.gov/documents/2026/10/09/2026-20726/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-over-the-counter
